WST

West Pharmaceutical Services, Inc. NYSE

Healthcare ·Medical - Instruments & Supplies ·US · westpharma.com

$300.68

Mkt Cap $21.9B

52w Low $202.79 81.9% of range 52w High $322.34

50d MA $255.90 200d MA $258.49

P/E (TTM) 44.0x

EV/EBITDA 27.0x

P/B 6.8x

Debt/Equity 0.1x

ROE 18.1%

P/FCF 42.4x

RSI (14) —

ATR (14) —

Beta 1.15

50d MA $255.90

200d MA $258.49

Avg Volume 976.5K

About

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syr…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Apr 23, 2026	AMC	1.68	2.13	+26.8%	309.70	+2.0%	-1.1%	-2.4%	-5.7%	-4.6%	-3.9%	—	—
Feb 12, 2026	AMC	1.83	2.04	+11.5%	243.61	+0.1%	+2.8%	-0.2%	+1.9%	+0.1%	-1.0%	-1.4%	—
Oct 23, 2025	AMC	1.68	1.96	+16.7%	307.25	+0.2%	-3.2%	-6.5%	-7.7%	-7.3%	-9.3%	-10.8%	—
Jul 24, 2025	AMC	1.51	1.84	+21.9%	279.10	+0.0%	-5.6%	-7.6%	-9.4%	-10.7%	-14.3%	-11.4%	—
Apr 24, 2025	AMC	1.22	1.45	+18.9%	210.59	+2.0%	+1.9%	+2.6%	+1.4%	+0.3%	-0.2%	+0.2%	—
Feb 13, 2025	AMC	1.71	1.82	+6.4%	199.11	+1.8%	+7.8%	+6.0%	+1.7%	+2.3%	+5.9%	+16.2%	—
Oct 24, 2024	AMC	1.50	1.85	+23.3%	330.65	-0.8%	-6.9%	-6.1%	-3.7%	-5.3%	-6.9%	-3.3%	—
Jul 25, 2024	AMC	1.74	1.52	-12.6%	277.16	+0.9%	+2.7%	+4.0%	+8.1%	+10.5%	+9.1%	+9.5%	—
Apr 25, 2024	AMC	1.26	1.56	+23.8%	368.18	-1.1%	-2.1%	-3.7%	-2.9%	-1.3%	+0.1%	-11.1%	—
Feb 15, 2024	AMC	1.78	1.83	+2.8%	350.70	+0.0%	+3.2%	-0.1%	+1.6%	+2.6%	+4.8%	+12.8%	—
Oct 26, 2023	AMC	1.86	2.16	+16.1%	327.32	-0.5%	-2.0%	-2.3%	-2.8%	-1.7%	+0.1%	+8.1%	—
Jul 27, 2023	AMC	1.93	2.11	+9.3%	354.90	+1.1%	+3.0%	+3.7%	+4.7%	+4.4%	+4.2%	+13.7%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 27	Barclays	Maintains	Equal Weight → Equal Weight	—	$306.16	$304.40	-0.6%	-1.3%	-4.6%	-3.5%	-2.8%	-1.8%
Apr 14	Barclays	Maintains	Equal Weight → Equal Weight	—	$259.96	$261.18	+0.5%	+3.1%	+2.5%	+3.8%	+5.3%	+6.9%
Feb 13	Barclays	Maintains	Equal Weight → Equal Weight	—	$243.61	$243.94	+0.1%	+2.8%	-0.2%	+1.9%	+0.1%	-1.0%
Feb 3	Evercore ISI	Maintains	Outperform → Outperform	—	$237.50	$233.84	-1.5%	-2.8%	-0.2%	-2.5%	+4.8%	+4.8%
Oct 27	Barclays	Maintains	Equal Weight → Equal Weight	—	$297.47	$299.99	+0.8%	-3.4%	-4.7%	-4.2%	-6.4%	-5.2%
Oct 24	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$307.25	$307.94	+0.2%	-3.2%	-6.5%	-7.7%	-7.3%	-9.3%
Oct 24	UBS	Maintains	Buy → Buy	—	$307.25	$307.94	+0.2%	-3.2%	-6.5%	-7.7%	-7.3%	-9.3%
Oct 23	Evercore ISI	Maintains	Outperform → Outperform	—	$277.00	$301.06	+8.7%	+10.9%	+7.4%	+3.7%	+2.3%	+2.8%
Oct 2	Barclays	Maintains	Equal Weight → Equal Weight	—	$271.42	$269.52	-0.7%	+0.6%	+0.4%	-1.2%	-2.0%	-1.3%
Jul 25	Evercore ISI	Maintains	Outperform → Outperform	—	$279.10	$279.10	+0.0%	-5.6%	-7.6%	-9.4%	-10.7%	-14.3%
Jul 25	Barclays	Maintains	Equal Weight → Equal Weight	—	$279.10	$279.10	+0.0%	-5.6%	-7.6%	-9.4%	-10.7%	-14.3%
Jul 25	UBS	Maintains	Buy → Buy	—	$279.10	$279.10	+0.0%	-5.6%	-7.6%	-9.4%	-10.7%	-14.3%
Feb 14	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$199.11	$202.67	+1.8%	+7.8%	+6.0%	+1.7%	+2.3%	+5.9%
Dec 13	BofA Securities	Maintains	Buy → Buy	—	$331.62	$329.68	-0.6%	-0.5%	-0.3%	+0.8%	-1.9%	-1.4%
Dec 12	UBS	Upgrade	Neutral → Buy	—	$318.22	$320.90	+0.8%	+4.2%	+3.7%	+3.9%	+5.0%	+2.2%
Feb 16	UBS	Maintains	Neutral → Neutral	—	$350.70	$350.82	+0.0%	+3.2%	-0.1%	+1.6%	+2.6%	+4.8%
Feb 13	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$406.63	$402.43	-1.0%	-2.0%	+0.4%	-13.8%	-11.0%	-13.9%
Feb 7	Jefferies	Upgrade	Hold → Buy	—	$398.27	$408.08	+2.5%	+3.7%	+3.2%	+2.9%	+2.1%	+0.1%
Oct 27	Stephens & Co.	Maintains	Overweight → Overweight	—	$327.32	$325.73	-0.5%	-2.0%	-2.3%	-2.8%	-1.7%	+0.1%
Aug 30	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$412.41	$414.65	+0.5%	-0.8%	-1.3%	-1.1%	-2.1%	-1.8%
Aug 21	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$387.77	$389.90	+0.5%	+1.3%	+1.4%	+1.4%	+1.0%	+1.5%
Jul 28	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$354.90	$358.85	+1.1%	+3.0%	+3.7%	+4.7%	+4.4%	+4.2%
Jul 17	Stephens & Co.	Maintains	Overweight → Overweight	—	$385.13	$385.19	+0.0%	-0.4%	-0.1%	+0.1%	-1.7%	-2.0%
Jun 16	BofA Securities	Upgrade	Neutral → Buy	—	$359.80	$366.83	+2.0%	+0.6%	+1.8%	+2.5%	+2.5%	+2.0%
Apr 11	Stephens & Co.	Upgrade	Equal Weight → Overweight	—	$349.79	$355.06	+1.5%	+1.4%	+2.6%	+4.8%	+4.0%	+3.6%
Feb 17	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$319.77	$317.18	-0.8%	-1.9%	-4.1%	-4.4%	-2.4%	-3.0%
Dec 14	Deutsche Bank	Maintains	Hold → Hold	—	$251.90	$248.00	-1.5%	-3.3%	-5.9%	-10.2%	-9.4%	-9.6%
Dec 2	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$242.02	$235.58	-2.7%	+1.0%	-1.1%	-2.9%	-2.5%	-2.5%
Nov 30	UBS	Maintains	Neutral → Neutral	—	$223.50	$224.11	+0.3%	+5.0%	+8.3%	+9.3%	+7.1%	+5.1%
Oct 28	BofA Securities	Downgrade	Buy → Neutral	—	$221.23	$218.30	-1.3%	+1.9%	+4.0%	+3.7%	-0.8%	-5.4%
Oct 28	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$221.23	$218.30	-1.3%	+1.9%	+4.0%	+3.7%	-0.8%	-5.4%
Jul 29	Stephens & Co.	Maintains	Equal Weight → Equal Weight	—	$339.92	$338.85	-0.3%	+1.1%	-0.3%	-0.2%	+1.1%	+0.2%
Apr 29	BofA Securities	Maintains	Buy → Buy	—	$325.36	$323.07	-0.7%	-3.2%	-4.0%	-5.8%	-2.1%	-3.3%
Apr 29	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$325.36	$323.07	-0.7%	-3.2%	-4.0%	-5.8%	-2.1%	-3.3%
Sep 15	BofA Securities	Maintains	Buy → Buy	—	$452.06	$453.73	+0.4%	+0.1%	+0.5%	-0.8%	-1.6%	-0.9%
Jul 30	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$404.92	$406.72	+0.4%	+1.7%	+2.5%	+4.3%	+5.7%	+5.1%
Jul 30	Stephens & Co.	Maintains	Equal Weight → Equal Weight	—	$404.92	$406.72	+0.4%	+1.7%	+2.5%	+4.3%	+5.7%	+5.1%
Apr 30	Stephens & Co.	Maintains	Equal Weight → Equal Weight	—	$324.55	$324.84	+0.1%	+1.2%	+1.6%	+1.4%	+1.2%	+1.5%
Feb 19	Stephens & Co.	Maintains	Equal Weight → Equal Weight	—	$296.74	$297.68	+0.3%	-5.1%	-8.1%	-7.6%	-6.0%	-6.4%
Nov 10	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$286.54	$286.14	-0.1%	-2.5%	-0.5%	+1.1%	+1.5%	+1.9%
Nov 10	KeyBanc	Maintains	Overweight → Overweight	—	$286.54	$286.14	-0.1%	-2.5%	-0.5%	+1.1%	+1.5%	+1.9%
Oct 14	Stephens & Co.	Maintains	Equal Weight → Equal Weight	—	$299.48	$299.03	-0.2%	-3.8%	-2.7%	-2.5%	-4.5%	-4.2%
Apr 24	BofA Securities	Upgrade	Underperform → Neutral	—	$187.42	$190.00	+1.4%	+4.3%	+5.6%	+3.0%	+1.2%	+1.0%
Dec 12	BofA Securities	Downgrade	Neutral → Underperform	—	$146.67	$143.39	-2.2%	-0.2%	-0.2%	+0.4%	+1.2%	+1.8%
Dec 12	Bank of America	Downgrade	Neutral → Underperform	—	$146.67	$143.39	-2.2%	-0.2%	-0.2%	+0.4%	+1.2%	+1.8%
Jul 26	BofA Securities	Upgrade	Underperform → Neutral	—	$132.86	$134.30	+1.1%	+3.0%	+4.1%	+3.5%	+3.3%	+3.3%
Jul 26	Bank of America	Upgrade	Underperform → Neutral	—	$132.86	$134.30	+1.1%	+3.0%	+4.1%	+3.5%	+3.3%	+3.3%
May 1	Jefferies	Downgrade	Buy → Hold	—	$123.79	$121.45	-1.9%	-2.6%	-1.6%	-0.8%	-0.8%	-1.9%
Apr 23	William Blair	Maintains	Outperform → Outperform	—	$112.16	$113.42	+1.1%	+2.7%	+2.7%	+9.0%	+10.3%	+9.0%
Apr 25	BofA Securities	Downgrade	Neutral → Underperform	—	$92.00	$89.00	-3.3%	-4.3%	-2.0%	-3.3%	-4.1%	-4.6%

Recent Filings

8-K · 7.01 ! Medium

West Pharmaceutical Services, Inc. -- 8-K 7.01: Regulation FD Disclosure

West Pharmaceutical Services disclosed material information via Form 8-K on April 23, 2026, though the specific disclosure details are not provided in this filing excerpt.

Apr 23

8-K · 5.02 !!! Very High

West Pharmaceutical Services, Inc. -- 8-K 5.02: Executive Change

West Pharmaceutical Services' CEO and board chair announced plans to retire once a successor is identified, signaling a leadership transition that investors should monitor for potential operational continuity impacts.

Mar 9

8-K · 7.01 ! Medium

West Pharmaceutical Services, Inc. -- 8-K 7.01: Regulation FD Disclosure

West Pharmaceutical Services disclosed CFO personnel information in a Regulation FD filing, which typically indicates routine executive updates rather than material business developments affecting investor returns.

Feb 12

Data updated apr 27, 2026 10:02am · Source: massive.com